Mucositis - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 39 pages report, published by Global Markets Direct

Keywords : Mucositis Therapeutic Products under Development, Key Players in Mucositis Therapeutics, Mucositis Pipeline Overview, Mucositis Pipeline, Mucositis Pipeline Assessment

Report ThumbnailSeptember-2013
Mucositis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Mucositis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mucositis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucositis. Mucositis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Mucositis.
- A review of the Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mucositis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Mucositis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mucositis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Mucositis, H2 2013 7
  • Products under Development for Mucositis - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Early Clinical Stage Products, H2 2013 12
  • Discovery and Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 19
  • Assessment by Route of Administration, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 21
  • Assessment by Molecule Type, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 23
  • List of Tables
  • Number of Products Under Development for Mucositis, H2 2013 7
  • Products under Development for Mucositis - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • Piramal Healthcare Limited, H2 2013 16
  • Spectrum Pharmaceuticals, Inc., H2 2013 17
  • Avaxia Biologics, Inc., H2 2013 18
  • Assessment by Monotherapy Products, H2 2013 19
  • Assessment by Stage and Route of Administration, H2 2013 21
  • Assessment by Stage and Molecule Type, H2 2013 23
  • Mucositis Therapeutics - Drug Profile Updates 31
  • Mucositis Therapeutics - Discontinued Products 32
  • Mucositis Therapeutics - Dormant Products 33
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Mucositis Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Mucositis 7
  • Mucositis Therapeutics under Development by Companies 9
  • Mucositis Therapeutics under Investigation by Universities/Institutes 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Early Clinical Stage Products 12
  • Comparative Analysis 12
  • Discovery and Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Mucositis Therapeutics - Products under Development by Companies 14
  • Mucositis Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Mucositis Therapeutics Development 16
  • Piramal Healthcare Limited 16
  • Spectrum Pharmaceuticals, Inc. 17
  • Avaxia Biologics, Inc. 18
  • Mucositis - Therapeutics Assessment 19
  • Assessment by Monotherapy Products 19
  • Assessment by Route of Administration 20
  • Assessment by Molecule Type 22
  • Drug Profiles 24
  • levoleucovorin calcium - Drug Profile 24
  • Product Description 24
  • Mechanism of Action 24
  • R&D Progress 24
  • P-276 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • CR-3294 - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • Drug For Mucositis - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • Melatonin Gel - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • Mucositis Therapeutics - Drug Profile Updates 31
  • Mucositis Therapeutics - Discontinued Products 32
  • Mucositis Therapeutics - Dormant Products 33
  • Mucositis - Product Development Milestones 34
  • Featured News & Press Releases 34
  • Sep 06, 2012: Research Shows Rapamycin Could Protect Against Sore Mouth After Radiotherapy 34
  • Aug 02, 2011: Access Pharmaceuticals MuGard Added To Humana's Pharmacy Drug Benefit Network 34
  • Jul 13, 2011: BioAlliance Announces Validation Of Orphan Drug Designation Application For Clonidine Lauriad 35
  • Jun 24, 2011: BioAlliance Pharma Submits Application For Orphan Medicinal Product Designation For Clonidine Lauriad In Europe And US 35
  • Jun 04, 2011: SciClone's SCV-07 Demonstrates Antitumor Activity In Various Cancer Xenograft Studies In Mice 35
  • May 18, 2011: SciClone To Present New Preclinical Data On SCV-07 At 2011 ASCO Annual Meeting 36
  • Feb 09, 2011: Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential 37
  • Appendix 38
  • Methodology 38
  • Coverage 38
  • Secondary Research 38
  • Primary Research 38
  • Expert Panel Validation 38
  • Contact Us 39
  • Disclaimer 39

Please select a license type

Share

Related Products

Global Markets DirectMucositis - Pipeline Review, H2 2013Product ThumbnailMucositis - Pipeline Review, H2 2013, Industry ReportProduct #: 113357
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved